Fibralign Corporation Appoints Dimitris Dionysiou, Ph.D., M.D. as Chief Medical Officer

May 24, 2017

Fibralign Corporation, a developer of advanced therapeutic medical devices, announces the appointment of Dimitris Dionysiou, Ph.D., M.D. as its Chief Medical Officer. Dr. Dionysiou joins the Company during the clinical phase for its first product, the BioBridge® Collagen Matrix where it will be evaluated for its effectiveness for treating secondary lymphedema.

Dr. Dionyssiou is a renowned plastic and reconstructive microsurgeon who is internationally recognized for his research and clinical work in breast reconstruction and surgical treatments for lymphedema. Dr. Dionysiou joins Fibralign from Aristotle University of Thessaloniki (Greece) where he serves as Assistant Professor in Plastic Surgery (Clinical). He has published over 40 medical papers and has presented in over 100 conferences on topics related to lymphedema and breast reconstruction. In this new role, Dr. Dionyssiou will also serve as a Visiting Assistant Professor, Division of Plastic and Reconstructive Surgery at Stanford University.

“We are thrilled to have Dr. Dionysiou join the Fibralign team,” said Greg King, Fibralign’s Chief Executive Officer. “Dr. Dionysiou’s extensive experience in microsurgery, and specifically in the treatment of lymphedema, provides unique and important skills as we move forward with clinical studies in the US and Europe.”

“I am delighted to join Fibralign and help in advancing clinical evaluation of BioBridge for treating and preventing secondary lymphedema,” stated Dr. Dionysiou. “I look forward to working with the Fibralign team and our collaborators in advancing the quality of care in treating this disease, as well as exploring other applications for Fibralign’s novel technology.”

 

BioBridge Collagen Matrix:

BioBridge is a sterile implantable biocompatible and biodegradable surgical mesh that has 510(k) clearance from the FDA for use in surgery to reinforce and repair soft tissue where weakness and deficiencies exist. This novel medical device is made of highly purified collagen and is created with Fibralign’s patented Nanoweave® technology. The device is not cleared for the treatment of lymphedema. Recently the FDA approved a clinical study being led by Stanford University that plans to evaluate using BioBridge in a surgical procedure for patients with secondary lymphedema.

About Fibralign:

Fibralign Corporation produces advanced therapeutic medical devices that utilize its patented Nanoweave® 3D scaffolding technology to meet major unmet medical needs. For further information, please visit https://www.fibralignbio.com.

For more additional information regarding Fibralign, please contact Jennifer K. Zimmons, Ph.D. at (917) 214-3514 or jzimmons@zimmonsic.com.

 

 

Fibralign Announces CE Mark Approval for BioBridge®

Fibralign Announces CE Mark Approval for BioBridge®

European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...

read more
Fibralign Announces Strategic Partnership with Terumo

Fibralign Announces Strategic Partnership with Terumo

Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced...

read more
Fibralign Awarded SBIR Phase IIS from Department of Defense

Fibralign Awarded SBIR Phase IIS from Department of Defense

Fibralign announced today that it has been awarded a Small Business Innovation Research (SBIR) Sequential Phase II (Phase IIS) from the Department of Defense (DoD) Defense Health Program (DHP). This two-year grant provides $996,609 in funding to continue advancing...

read more